Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Persistence to Biologic Therapy Among Patients With Ankylosing Spondylitis: An Observational Study Using the OPAL Dataset

Hedley Griffiths, Tegan Smith, Christopher Mack, Jo Leadbetter, Belinda Butcher, Mustafa Acar and Sabina Ciciriello
The Journal of Rheumatology August 2021, jrheum.201551; DOI: https://doi.org/10.3899/jrheum.201551
Hedley Griffiths
This study received financial assistance from Janssen-Cilag Pty Limited, Australia. The study was conducted independently by OPAL with review and input on the study start-up documents (protocol and statistical analysis plan) as well as review and input into final manuscript by a Janssen staff member (MA). H. Griffiths, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Barwon Rheumatology Service, Geelong; T. Smith, PhD, OPAL Rheumatology Ltd, Sydney; C. Mack, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Coast Joint Care, Maroochydore; J. Leadbetter, PhD, A Stat, WriteSource Medical, Lane Cove; B. Butcher, PhD, CMPP, A Stat, WriteSource Medical, Lane Cove, and University of New South Wales, Kensington; M. Acar, PhD, Janssen-Cilag, Macquarie Park; S. Ciciriello, MBBS, FRACP, PhD, OPAL Rheumatology Ltd, Sydney, and Royal Melbourne Hospital, Parkville, Australia. MA is an employee of Janssen-Cilag Pty Limited, Australia. The remaining authors declare no conflicts of interest relevant to this study. Address correspondence to Dr. H. Griffiths, Barwon Rheumatology Service, 156 Bellerine Street, Geelong, 3220 VIC, Australia. Email: hedley{at}brservice.com.au. Accepted for publication July 22, 2021.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hedley Griffiths
Tegan Smith
This study received financial assistance from Janssen-Cilag Pty Limited, Australia. The study was conducted independently by OPAL with review and input on the study start-up documents (protocol and statistical analysis plan) as well as review and input into final manuscript by a Janssen staff member (MA). H. Griffiths, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Barwon Rheumatology Service, Geelong; T. Smith, PhD, OPAL Rheumatology Ltd, Sydney; C. Mack, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Coast Joint Care, Maroochydore; J. Leadbetter, PhD, A Stat, WriteSource Medical, Lane Cove; B. Butcher, PhD, CMPP, A Stat, WriteSource Medical, Lane Cove, and University of New South Wales, Kensington; M. Acar, PhD, Janssen-Cilag, Macquarie Park; S. Ciciriello, MBBS, FRACP, PhD, OPAL Rheumatology Ltd, Sydney, and Royal Melbourne Hospital, Parkville, Australia. MA is an employee of Janssen-Cilag Pty Limited, Australia. The remaining authors declare no conflicts of interest relevant to this study. Address correspondence to Dr. H. Griffiths, Barwon Rheumatology Service, 156 Bellerine Street, Geelong, 3220 VIC, Australia. Email: hedley{at}brservice.com.au. Accepted for publication July 22, 2021.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Mack
This study received financial assistance from Janssen-Cilag Pty Limited, Australia. The study was conducted independently by OPAL with review and input on the study start-up documents (protocol and statistical analysis plan) as well as review and input into final manuscript by a Janssen staff member (MA). H. Griffiths, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Barwon Rheumatology Service, Geelong; T. Smith, PhD, OPAL Rheumatology Ltd, Sydney; C. Mack, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Coast Joint Care, Maroochydore; J. Leadbetter, PhD, A Stat, WriteSource Medical, Lane Cove; B. Butcher, PhD, CMPP, A Stat, WriteSource Medical, Lane Cove, and University of New South Wales, Kensington; M. Acar, PhD, Janssen-Cilag, Macquarie Park; S. Ciciriello, MBBS, FRACP, PhD, OPAL Rheumatology Ltd, Sydney, and Royal Melbourne Hospital, Parkville, Australia. MA is an employee of Janssen-Cilag Pty Limited, Australia. The remaining authors declare no conflicts of interest relevant to this study. Address correspondence to Dr. H. Griffiths, Barwon Rheumatology Service, 156 Bellerine Street, Geelong, 3220 VIC, Australia. Email: hedley{at}brservice.com.au. Accepted for publication July 22, 2021.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jo Leadbetter
This study received financial assistance from Janssen-Cilag Pty Limited, Australia. The study was conducted independently by OPAL with review and input on the study start-up documents (protocol and statistical analysis plan) as well as review and input into final manuscript by a Janssen staff member (MA). H. Griffiths, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Barwon Rheumatology Service, Geelong; T. Smith, PhD, OPAL Rheumatology Ltd, Sydney; C. Mack, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Coast Joint Care, Maroochydore; J. Leadbetter, PhD, A Stat, WriteSource Medical, Lane Cove; B. Butcher, PhD, CMPP, A Stat, WriteSource Medical, Lane Cove, and University of New South Wales, Kensington; M. Acar, PhD, Janssen-Cilag, Macquarie Park; S. Ciciriello, MBBS, FRACP, PhD, OPAL Rheumatology Ltd, Sydney, and Royal Melbourne Hospital, Parkville, Australia. MA is an employee of Janssen-Cilag Pty Limited, Australia. The remaining authors declare no conflicts of interest relevant to this study. Address correspondence to Dr. H. Griffiths, Barwon Rheumatology Service, 156 Bellerine Street, Geelong, 3220 VIC, Australia. Email: hedley{at}brservice.com.au. Accepted for publication July 22, 2021.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Belinda Butcher
This study received financial assistance from Janssen-Cilag Pty Limited, Australia. The study was conducted independently by OPAL with review and input on the study start-up documents (protocol and statistical analysis plan) as well as review and input into final manuscript by a Janssen staff member (MA). H. Griffiths, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Barwon Rheumatology Service, Geelong; T. Smith, PhD, OPAL Rheumatology Ltd, Sydney; C. Mack, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Coast Joint Care, Maroochydore; J. Leadbetter, PhD, A Stat, WriteSource Medical, Lane Cove; B. Butcher, PhD, CMPP, A Stat, WriteSource Medical, Lane Cove, and University of New South Wales, Kensington; M. Acar, PhD, Janssen-Cilag, Macquarie Park; S. Ciciriello, MBBS, FRACP, PhD, OPAL Rheumatology Ltd, Sydney, and Royal Melbourne Hospital, Parkville, Australia. MA is an employee of Janssen-Cilag Pty Limited, Australia. The remaining authors declare no conflicts of interest relevant to this study. Address correspondence to Dr. H. Griffiths, Barwon Rheumatology Service, 156 Bellerine Street, Geelong, 3220 VIC, Australia. Email: hedley{at}brservice.com.au. Accepted for publication July 22, 2021.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Belinda Butcher
Mustafa Acar
This study received financial assistance from Janssen-Cilag Pty Limited, Australia. The study was conducted independently by OPAL with review and input on the study start-up documents (protocol and statistical analysis plan) as well as review and input into final manuscript by a Janssen staff member (MA). H. Griffiths, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Barwon Rheumatology Service, Geelong; T. Smith, PhD, OPAL Rheumatology Ltd, Sydney; C. Mack, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Coast Joint Care, Maroochydore; J. Leadbetter, PhD, A Stat, WriteSource Medical, Lane Cove; B. Butcher, PhD, CMPP, A Stat, WriteSource Medical, Lane Cove, and University of New South Wales, Kensington; M. Acar, PhD, Janssen-Cilag, Macquarie Park; S. Ciciriello, MBBS, FRACP, PhD, OPAL Rheumatology Ltd, Sydney, and Royal Melbourne Hospital, Parkville, Australia. MA is an employee of Janssen-Cilag Pty Limited, Australia. The remaining authors declare no conflicts of interest relevant to this study. Address correspondence to Dr. H. Griffiths, Barwon Rheumatology Service, 156 Bellerine Street, Geelong, 3220 VIC, Australia. Email: hedley{at}brservice.com.au. Accepted for publication July 22, 2021.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabina Ciciriello
This study received financial assistance from Janssen-Cilag Pty Limited, Australia. The study was conducted independently by OPAL with review and input on the study start-up documents (protocol and statistical analysis plan) as well as review and input into final manuscript by a Janssen staff member (MA). H. Griffiths, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Barwon Rheumatology Service, Geelong; T. Smith, PhD, OPAL Rheumatology Ltd, Sydney; C. Mack, MBBS, FRACP, OPAL Rheumatology Ltd, Sydney, and Coast Joint Care, Maroochydore; J. Leadbetter, PhD, A Stat, WriteSource Medical, Lane Cove; B. Butcher, PhD, CMPP, A Stat, WriteSource Medical, Lane Cove, and University of New South Wales, Kensington; M. Acar, PhD, Janssen-Cilag, Macquarie Park; S. Ciciriello, MBBS, FRACP, PhD, OPAL Rheumatology Ltd, Sydney, and Royal Melbourne Hospital, Parkville, Australia. MA is an employee of Janssen-Cilag Pty Limited, Australia. The remaining authors declare no conflicts of interest relevant to this study. Address correspondence to Dr. H. Griffiths, Barwon Rheumatology Service, 156 Bellerine Street, Geelong, 3220 VIC, Australia. Email: hedley{at}brservice.com.au. Accepted for publication July 22, 2021.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

Abstract

Objective To describe the treatment response and persistence to biologic disease-modifying antirheumatic drug (bDMARD) therapy in patients with ankylosing spondylitis (AS) in a real-world Australian cohort.

Methods This was a retrospective, noninterventional cohort study that extracted data for patients with AS from the Optimising Patient outcomes in Australian RheumatoLogy (OPAL) dataset for the period of August 2006 to September 2019. Patients were classified as either bDMARD initiators if they commenced a bDMARD during the sampling window, or bDMARD-naïve if they did not. Results were summarized descriptively. Treatment persistence was calculated using Kaplan-Meier methods. Differences in treatment persistence were explored using log-rank tests.

Results There were 5048 patients with AS identified. Of these, 2597 patients initiated bDMARDs and 2451 remained bDMARD-naïve throughout the study window. Treatment with first-, second-, and third-line bDMARDs significantly reduced disease activity. Median persistence on first-line bDMARDs was 96 months (95% CI 85–109), declining to 19 months (95% CI 16–22) in second-line therapy, and 15 months (95% CI 11–18) in third-line therapy. Median persistence was longest for the golimumab (GOL) group in all lines of therapy and shortest for the etanercept (ETN) group. Differences in persistence rates according to the time period that bDMARDs were prescribed (pre- and post-2012) were also seen for ETN and adalimumab.

Conclusion In this cohort, all bDMARDs effectively reduced AS disease activity. Treatment persistence was sustained for up to 8 years for patients remaining on their first bDMARD, longer than on subsequent agents. Further research is needed to determine its influence on treatment recommendations.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology: 53 (11)
The Journal of Rheumatology
Vol. 53, Issue 11
1 Nov 2026
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Persistence to Biologic Therapy Among Patients With Ankylosing Spondylitis: An Observational Study Using the OPAL Dataset
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Persistence to Biologic Therapy Among Patients With Ankylosing Spondylitis: An Observational Study Using the OPAL Dataset
Hedley Griffiths, Tegan Smith, Christopher Mack, Jo Leadbetter, Belinda Butcher, Mustafa Acar, Sabina Ciciriello
The Journal of Rheumatology Aug 2021, jrheum.201551; DOI: 10.3899/jrheum.201551

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Persistence to Biologic Therapy Among Patients With Ankylosing Spondylitis: An Observational Study Using the OPAL Dataset
Hedley Griffiths, Tegan Smith, Christopher Mack, Jo Leadbetter, Belinda Butcher, Mustafa Acar, Sabina Ciciriello
The Journal of Rheumatology Aug 2021, jrheum.201551; DOI: 10.3899/jrheum.201551
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Sex Differences in Clinical Need, Willingness, and Surgeon Recommendations for Total Knee Arthroplasty: A Cross-Sectional Study
  • Validation of Handheld Ultrasound Devices for Point-of-Care Use in Rheumatology: Focus on Synovitis, Doppler Activity, Erosions, and Tendon Lesions
  • Persistent Opioid Exposure in Older Adults With Rheumatic Disease: National Patterns, Disparities, and Cross-Specialty Prescribing
Show more Article

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire